Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Rating of “Hold” by Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned a consensus rating of “Hold” from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $54.50.

Several equities analysts recently weighed in on the company. Wells Fargo & Company increased their target price on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a research note on Wednesday, January 7th. Bank of America raised shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Wednesday, February 4th. Piper Sandler reaffirmed an “overweight” rating and set a $49.00 price target (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Finally, Benchmark increased their price target on shares of Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd.

Omnicell Stock Performance

Shares of OMCL opened at $40.80 on Friday. Omnicell has a 1 year low of $22.66 and a 1 year high of $55.00. The company’s 50 day simple moving average is $44.86 and its 200 day simple moving average is $38.14. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 1,020.26, a PEG ratio of 1.48 and a beta of 0.79. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm had revenue of $313.98 million during the quarter, compared to analysts’ expectations of $313.36 million. During the same period in the previous year, the firm posted $0.60 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, sell-side analysts predict that Omnicell will post 1.09 EPS for the current year.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the transaction, the executive vice president owned 91,674 shares in the company, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.52% of the company’s stock.

Hedge Funds Weigh In On Omnicell

A number of large investors have recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of Omnicell in the 2nd quarter valued at about $26,000. First Horizon Corp acquired a new position in Omnicell during the third quarter valued at approximately $31,000. Farther Finance Advisors LLC grew its stake in Omnicell by 784.8% during the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after buying an additional 1,036 shares during the period. Clearstead Advisors LLC grew its stake in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after buying an additional 1,218 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Omnicell in the fourth quarter worth $58,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.